BUN

MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

Retrieved on: 
Mercredi, juin 21, 2023
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, GFR, Hyperkalemia, Carcinoma, Radiation, Nephrotoxicity, Biodistribution, Blood urea nitrogen, Dosimetry, Half-life, Creatinine, Overalls, Quality of life, Glomerular filtration rate, NET, Dicarboxylic acid, Vomiting, Serum albumin, MD, Patient, Cancer, Kidney, Creatine, Nausea, BUN, PRRT, Phosphorus, Dietary supplement, Safety

Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.
  • A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia.
  • EBTATE administration appears to be safe without amino acid infusion.”
    Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs.
  • Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion.

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercredi, mai 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Pharmacy, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Heart, Deafness, Huber loss, Edema, Food and Drug Administration, Hepatic encephalopathy, Medicare Part D, Prescription, Research, Part, Oliguria, History, Trial of the century, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Physician, Patient, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Food, Anuria, Security (finance), Pharmaceutical industry, Health insurance, Video game, Medical device, BURLINGTON

BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. 

Key Points: 
  • Ended the first quarter of 2023 with cash, cash equivalents and short-term investments of $116.1 million.
  • Net product revenues were $2.1 million and cost of product revenues were $0.6 million for the first quarter of 2023.
  • Research and development expenses were $2.1 million for the first quarter of 2023, compared to $4.3 million for the first quarter of 2022.
  • As of March 31, 2023, scPharmaceuticals’ total shares outstanding was 35,769,073.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s first quarter 2023 results today, Wednesday, May 10, at 4:30 p.m.

Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Retrieved on: 
Vendredi, mai 5, 2023
Medical Supplies, Biotechnology, FDA, Other Health, Health, Pharmaceutical, Pets, Medical Devices, Consumer, Veterinary, Clinical Trials, Exercise, Osteoarthritis, Inc., Blood urea nitrogen, Prevalence, Senior, Veterinarian, Overalls, European Medicines Agency, State university system, Human, Quality of life, Zoetis, Dermatitis, North Carolina State University, EMA, Urinary tract infection, Translational research, Dog, Pain management, Nerve growth factor, NGF, Chronic pain, Regulation of tobacco by the U.S. Food and Drug Administration, BUN, NYSE, Food, Vaccine, Hunting, OA, Pain

Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.
  • Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life.
  • The pain of OA can impact a dog’s physical and emotional health.
  • This once monthly injection works differently from other pain medications – it’s unique mode of action targets Nerve Growth Factor (NGF), a key component of OA pain.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Mercredi, mars 22, 2023
Hypersensitivity, Furosemide, Oaktree Capital Management, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Marketing, Creatinine, Cirrhosis, Dehydration, Tinnitus, Heart, Glucose, Huber loss, Deafness, Edema, Hepatic encephalopathy, Medicare Part D, Research, Oliguria, History, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Patient, Investment, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Anuria, Pharmaceutical industry, Cryptocurrency, Security (finance), Video game, Finance, BURLINGTON

BURLINGTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2022 and provided a business update. 

Key Points: 
  • Entered into $100 million secured debt financing agreement with funds managed by Oaktree Capital Management in October 2022.
  • scPharmaceuticals ended the fourth quarter 2022 with $118.4 million in cash, cash equivalents, restricted cash and investments, compared to $75.5 million as of December 31, 2021.
    scPharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2022, compared to $7.3 million for the fourth quarter of 2021.
  • Research and development expenses were $2.3 million for the fourth quarter of 2022, compared to $4.5 million for the fourth quarter of 2021.
  • General and administrative expenses were $7.2 million for the fourth quarter of 2022, compared to $2.2 million for the fourth quarter of 2021.

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

Retrieved on: 
Mardi, février 21, 2023
BUN, Coma, Furosemide, NYHA, Edema, Diuresis, Ascites, Organic acid, Huber loss, Ototoxicity, Deafness, Uric acid, Thrombosis, Erythema, Hepatic encephalopathy, CO2, Patient, Dehydration, Webcast, Urinary retention, Blood volume, Cerebral edema, Creatinine, Kidney, Tinnitus, Hypersensitivity, New York Heart Association Functional Classification, Anuria, Embolism, Oliguria, Hypoproteinemia, Benign prostatic hyperplasia, Urine, Azotemia, Cirrhosis, Glucose, History, Bruise, Congestion, Pharmaceutical industry

FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.

Key Points: 
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • “We are thrilled to announce the commercial availability of FUROSCIX for patients suffering from worsening heart failure due to congestion,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

Retrieved on: 
Lundi, janvier 30, 2023
Medicare Part D, Creatinine, Huber loss, Thrombosis, Oliguria, Anuria, Bruise, BUN, Uric acid, Urinary retention, Coma, Medicare, Ascites, Tinnitus, Urine, Organic acid, Hepatic encephalopathy, Benign prostatic hyperplasia, Webcast, History, Furosemide, Deafness, Hypersensitivity, Hypoproteinemia, Medicaid, Commercial, Erythema, New York Heart Association Functional Classification, NYHA, Embolism, Ototoxicity, Patient, CO2, Edema, Congestion, FDA, SVP, Cerebral edema, Azotemia, Cirrhosis, Blood volume, Senior, Kidney, Diuresis, Glucose, Dehydration, Heart failure, Pharmaceutical industry, Medical imaging

“Since obtaining FDA approval for FUROSCIX in October 2022, we have been working tirelessly to prepare for a robust commercial launch, which is targeted for February 20th,” stated John Tucker, Chief Executive Officer.

Key Points: 
  • “Since obtaining FDA approval for FUROSCIX in October 2022, we have been working tirelessly to prepare for a robust commercial launch, which is targeted for February 20th,” stated John Tucker, Chief Executive Officer.
  • Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
  • In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

Retrieved on: 
Lundi, décembre 19, 2022
Urine, Ascites, Ototoxicity, Carroll School of Management, NYHA, Congestion, Erythema, Coma, Uric acid, Thrombosis, Sarbanes–Oxley Act, CFO, Huber loss, PricewaterhouseCoopers, Boston College, CO2, Dehydration, Cerebral edema, Anuria, Embolism, Bruise, Patient, Azotemia, Furosemide, Cirrhosis, Benign prostatic hyperplasia, Organic acid, Deafness, Hypoproteinemia, Diuresis, BUN, Heart failure, Edema, Oliguria, Blood volume, History, Hypersensitivity, Bentley University, Glucose, Tinnitus, Senior, Creatinine, Kidney, Urinary retention, Hepatic encephalopathy, New York Heart Association Functional Classification, Pharmaceutical industry, Medical imaging, Finance

BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Rachael Nokes as Chief Financial Officer.

Key Points: 
  • BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Rachael Nokes as Chief Financial Officer.
  • Ms. Nokes previously served as scPharmaceuticals’ Senior Vice President of Finance.
  • “With eight years of exemplary service at the company, I believe Rachael is an outstanding choice for the CFO role as we prepare for the commercial launch of FUROSCIX®,” stated John Tucker, President and Chief Executive Officer of scPharmaceuticals.
  • She joined scPharmaceuticals in 2014 from BG Medicine Inc., a publicly traded medical device company, where she was Director of Accounting.

Global Blood Testing Market Report 2022: Growing Demand for Safe Blood and Blood Products Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Mercredi, décembre 21, 2022
Medical Supplies, Health, Food, Federal Trade Commission, Fever Dream, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Knowledge, USD, Diarrhea, CLIA, Microbiology, Growth, Centers for Medicare & Medicaid Services, BUN, Malaria, Investment, FDA, Hospital, Conditional sentence, Prevalence, Diagnosis, CMS, Medicare, Medical device, Pharmaceutical industry, Vaccine

The "Global Blood Testing Market Bytest type, By end user & By region-2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Blood Testing Market Bytest type, By end user & By region-2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Growing demand for safe blood and blood products among healthcare institutions around the world is a major driver fuelling market expansion.
  • Global blood testing market is segmented on the basis of test type, end-user, and region.
  • By test type, the market is segmented into glucose testing, lipid panel testing, BUN testing, A1C testing, and others.

DECKED Partners with Pearson's to Fuel Today's Missions

Retrieved on: 
Jeudi, août 11, 2022
Salted Nut Roll, Tool Box, Multimedia, BUN, Pearson, Pearson's Candy Company, Pearson's, OH, Marketing, Mark (given name), View, VP, ID, Cassette tape

KETCHUM, Idaho, Aug. 11, 2022 /PRNewswire/ -- DECKED, the folks making American-made gear and tool handling systems for people working and recreating out of vehicles, has joined forces with Pearson Candy Company to share the ultimate active person's snack with their customers– a peanut-packed Salted Nut Roll. DECKED is committed to customer satisfaction and will be including a Salted Nut Roll, at no additional cost, with every Drawer System, Tool Box, and CargoGlide to help fuel new DECKED owners' assembly and installation. DECKED and Pearson's are both invested in providing products to brighten the day of their hard working and harder playing customers.

Key Points: 
  • DECKED is committed to customer satisfaction and will be including a Salted Nut Roll, at no additional cost, with every Drawer System, Tool Box, and CargoGlide to help fuel new DECKED owners' assembly and installation.
  • DECKED and Pearson's are both invested in providing products to brighten the day of their hard working and harder playing customers.
  • Pearson's is now contributing a Salted Nut Roll with every new DECKED system purchased, providing an energizing jumpstart to the install process and providing a little extra fuel to get the job done.
  • "DECKED takes truck bed organization to the next level while having a lot of fun along the way.

Insights on the Renal Biomarkers Global Market to 2027 - by Biomarker Type, Diagnostic Technique, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Vendredi, juin 17, 2022
Health, Biotechnology, Chronic kidney disease, Metabolomics, GFR, Industry, Mortality, COVID-19, Urine test strip, Genomics, Glomerular filtration rate, Gene, Non-communicable disease, Proteomics, Blood urea nitrogen, Acute kidney injury, Hospital, Lipid, Growth, Disease, Hypertension, Protein, AKI, SCR, ADPKD, CKD, MicroRNA, Biomarker, Degenerative disease, HIV disease progression rates, Diagnosis, Cell, BUN, Transplant glomerulopathy, Risk, Diabetes, Pharmaceutical industry, Medical imaging, Potash

As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.

Key Points: 
  • As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
  • How has the global renal biomarkers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global renal biomarkers market?
  • What is the structure of the global renal biomarkers market and who are the key players?